Malaria vaccine technology roadmap
Update launched November 2013
The updated Malaria Vaccine Roadmap represents the result of a review process facilitated by the World Health Organization (WHO), which worked with the Malaria Vaccine Funders Group to update the vision and strategic goals of the first publication. Originally launched at the 2006 WHO Global Vaccine Research Forum and supported by the Funders Group, the Roadmap forms a strategic framework that underpins the activities of the global malaria vaccine research and development (R&D) community.
This update responds to the recognition that the malaria epidemiological and control status has changed markedly since 2006 when the Roadmap was originally launched. For instance, substantial changes in malaria epidemiology are now being observed in many settings following a reduction in malaria transmission, which has occurred in association with the scale-up of malaria control measures. The reduction in malaria transmission is associated with a shift in the peak age of clinical malaria to older children, as well as an increase in the median age of malaria-related hospitalization in some settings. In response to these developments and acknowledging substantial changes in the strategic direction for malaria research, the shared vision and strategic goals of the Roadmap have been expanded.
The vision and goals now encompass the current ambitious aims of the global malaria community, which include prevention of malaria disease and deaths, accompanied by the accepted goals of progressive malaria elimination and—ultimately— global eradication. In addition, the revision includes the need to address Plasmodium vivax malaria infections (in contrast to Plasmodium falciparum alone), all malaria-endemic areas (in contrast to sub-Saharan Africa alone), and all ages (in contrast to children younger than five only).
Safe and effective vaccines against Plasmodium falciparum and Plasmodium vivax that prevent disease and death and prevent transmission to enable malaria eradication.
By 2030, license vaccines targeting Plasmodium falciparum and Plasmodium vivax that encompass the following two objectives, for use by the international public health community:
- Development of malaria vaccines with protective efficacy of at least 75 percent against clinical malaria suitable for administration to appropriate at-risk groups in malaria-endemic areas.
- Development of malaria vaccines that reduce transmission of the parasite and thereby substantially reduce the incidence of human malaria infection. This will enable elimination in multiple settings. Vaccines to reduce transmission should be suitable for administration in mass campaigns.
WHO gratefully acknowledges the many individuals who contributed to the extensive consultative process. Please see the file below for full acknowledgements.
- WHO Global Malaria Programme
Q&A on RTS,S/AS01 malaria vaccine
- Other WHO information on malaria vaccines
For further information please contact email@example.com